NCT03399513 - Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

December 23, 2023

Study Completion Date

December 23, 2023

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Ibrutinib Oral Capsule [Imbruvica]

Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)

DRUG

R-CHOEP chemotherapy

Immunochemotherapy

Trial Locations (12)

13125

HELIOS Hospital Berlin-Buch, Berlin

18057

Rostock University Medical Center, Rostock

20246

University Hospital Hamburg-Eppendorf, Hamburg

32429

Johannes Wesling Hospital Minden, Minden

37075

University Hospital Göttingen, Göttingen

48149

University Hospital Muenster, Münster

50937

University Hospital Cologne, Cologne

66421

Saarland University Hospital, Homburg

69120

University Hospital Heidelberg, Heidelberg

72076

University Hospital Tuebingen, Tübingen

89081

University Hospital Ulm, Ulm

09116

Hospital Chemnitz, Chemnitz

All Listed Sponsors

collaborator

Janssen-Cilag G.m.b.H

INDUSTRY

lead

University Hospital Muenster

OTHER